Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hologic divests drug

This article was originally published in The Gray Sheet

Executive Summary

Women's health device maker divests Gestiva, its "non-core" drug for the prevention of preterm birth, to KV Pharmaceutical for $82 million in a deal announced Jan. 22. The drug, which is pending FDA approval, was part of Hologic's October purchase of cervical cancer test firm Cytyc (1"The Gray Sheet" May 28, 2007, p. 10)

You may also be interested in...



Hologic/Cytyc Merger Combines Diverse Women’s Health Device Portfolios

The combination of mammography device maker Hologic and cervical cancer test firm Cytyc will create a women's health powerhouse with $1.44 billion in combined annual revenues

Japanese Firms Pursued Over Edirol Ingredient

Chugai is pursuing further Japanese litigation over generic rivals to its Edirol brand, this time concerning the eldecalcitol ingredient produced by Nissan Chemical.

European Commission Decides CBD Is Not A Drug Opening Up Novel Food Pathway

The European Commission has unexpectedly concluded that CBD should not be considered as a drug opening up the path to a regulated EU market for the cannabinoid as a novel food.

UsernamePublicRestriction

Register

OM006664

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel